Literature DB >> 20428827

miRNA-regulated expression of oncogenes and tumor suppressor genes in the cisplatin-inhibited growth of K562 cells.

Shu-Yang Xie1, You-Jie Li, Ping-Yu Wang, Fei Jiao, Shuai Zhang, Wen-Juan Zhang.   

Abstract

To explore the mechanism of apoptosis induced by cisplatin, the expression of microRNAs (miRNAs) and regulating genes in K562 cells was analyzed using reverse transcription PCR, quantitative real-time PCR and enzyme-linked immunosorbent assays. Our results showed that miR-16, miR-34a-c, miR-17-5p and miR-125 were up-regulated, and their associated oncogenes (BCL2, E2F1 and E2F3, respectively) were down-regulated after cisplatin treatment. We also showed that miR-106 and miR-150 were down-regulated while their target genes (RB1 and P53, respectively) were up-regulated after cisplatin treatment. Moreover, miR-16, miR-34a-c and miR-17-5p proved to be upstream factors, regulating the expression of BCL2, E2F1 and E2F3, respectively. The oncogene E2F3 was down-regulated when RB1 expression was increased after treatment with antisense oligonucleotides (ASO). Similarly, BCL2 and E2F3 were down-regulated when P53 expression was elevated by ASO treatment. The study demonstrated that cisplatin induces K562 cells to apoptosis by reducing miR-106 which up-regulates RB1 or by inhibiting miR-150 which increases P53 expression.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20428827     DOI: 10.3892/or_00000813

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  14 in total

1.  Role of microRNA-150 in solid tumors.

Authors:  Fang Wang; Xiubao Ren; Xinwei Zhang
Journal:  Oncol Lett       Date:  2015-04-30       Impact factor: 2.967

2.  MiR-34a chemosensitizes bladder cancer cells to cisplatin treatment regardless of p53-Rb pathway status.

Authors:  Ruth L Vinall; Alexandra Z Ripoll; Sisi Wang; Chong-Xian Pan; Ralph W deVere White
Journal:  Int J Cancer       Date:  2011-12-02       Impact factor: 7.396

3.  Cisplatin upregulates MSH2 expression by reducing miR-21 to inhibit A549 cell growth.

Authors:  Yan-Xia Zhang; Zhen Yue; Ping-Yu Wang; You-Jie Li; Jia-Xuan Xin; Min Pang; Qing-Yin Zheng; Shu-Yang Xie
Journal:  Biomed Pharmacother       Date:  2012-12-28       Impact factor: 6.529

4.  MicroRNA expression profile of the hippocampus in a rat model of temporal lobe epilepsy and miR-34a-targeted neuroprotection against hippocampal neurone cell apoptosis post-status epilepticus.

Authors:  Kai Hu; Yuan-Yuan Xie; Chen Zhang; Dong-Sheng Ouyang; Hong-Yu Long; Dan-Ni Sun; Li-Li Long; Li Feng; Yi Li; Bo Xiao
Journal:  BMC Neurosci       Date:  2012-09-22       Impact factor: 3.288

5.  A novel pathway of TEF regulation mediated by microRNA-125b contributes to the control of actin distribution and cell shape in fibroblasts.

Authors:  Olga Gutierrez; Maria T Berciano; Miguel Lafarga; Jose L Fernandez-Luna
Journal:  PLoS One       Date:  2011-02-11       Impact factor: 3.240

6.  Cisplatin as an anti-tumor drug: cellular mechanisms of activity, drug resistance and induced side effects.

Authors:  Ana-Maria Florea; Dietrich Büsselberg
Journal:  Cancers (Basel)       Date:  2011-03-15       Impact factor: 6.639

Review 7.  MicroRNA and HER2-overexpressing cancer.

Authors:  Shizhen Emily Wang; Ren-Jang Lin
Journal:  Microrna       Date:  2013

Review 8.  Prognostic role of microRNA-150 in various carcinomas: a meta-analysis.

Authors:  Wei Wang; Xinshuai Wang; Yali Zhang; Dan Wang; Hui Gao; Lijuan Wang; Shegan Gao
Journal:  Onco Targets Ther       Date:  2016-03-11       Impact factor: 4.147

9.  miRNA-221 of exosomes originating from bone marrow mesenchymal stem cells promotes oncogenic activity in gastric cancer.

Authors:  Min Ma; Shilin Chen; Zhuo Liu; Hailong Xie; Hongyu Deng; Song Shang; Xiaohong Wang; Man Xia; Chaohui Zuo
Journal:  Onco Targets Ther       Date:  2017-08-22       Impact factor: 4.147

10.  API5 induces cisplatin resistance through FGFR signaling in human cancer cells.

Authors:  Han Sol Jang; Seon Rang Woo; Kwon-Ho Song; Hanbyoul Cho; Doo Byung Chay; Soon-Oh Hong; Hyo-Jung Lee; Se Jin Oh; Joon-Yong Chung; Jae-Hoon Kim; Tae Woo Kim
Journal:  Exp Mol Med       Date:  2017-09-08       Impact factor: 8.718

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.